Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FORA
FORA logo

FORA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.161
Open
2.150
VWAP
2.15
Vol
49.20K
Mkt Cap
67.17M
Low
2.150
Amount
105.96K
EV/EBITDA(TTM)
--
Total Shares
31.24M
EV
31.87M
EV/OCF(TTM)
11.04
P/S(TTM)
2.21
Forian Inc. is a healthtech company. It is a provider of data science-driven information and analytics solutions to the life science, healthcare and financial services industries. It provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure the operational, clinical and financial performance of customers within the healthcare and life sciences and financial services industries. It has expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. Its solutions include CHRONOS, Chartis, real-world evidence (RWE) and Kyber Data Science. CHRONOS combines open and closed claims, electronic health records, and social determinants of health data into a single, integrated model. It also provides researchers access to healthcare payers, providers, and clinical data with non-traditional healthcare sources, such as social determinants of health (SDoH) data, to uncover novel insights.
Show More

Events Timeline

(ET)
2025-08-25
13:29:16
Forian reveals it has received an unsolicited proposal to go private at $2.10 per share.
select
link
2024-11-13 (ET)
2024-11-13
15:06:39
Forian reports Q3 EPS (1c), consensus (3c)
select
2024-11-01 (ET)
2024-11-01
09:02:27
Forian acquires Kyber Data Science from TD Cowen, terms not disclosed
select

News

PRnewswire
7.0
04-24PRnewswire
Investor Rights Law Firm Investigates Multiple Companies
  • Legal Investigation Launched: Halper Sadeh LLC is investigating companies including Leggett & Platt, Select Medical Holdings, KORE Group Holdings, and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
  • Transaction Terms Scrutiny: Leggett & Platt shareholders are set to sell their shares for 0.1455 shares of Somnigroup common stock each, resulting in approximately 9% ownership of the combined company post-transaction, potentially limiting superior competing offers.
  • Cash Acquisition Proposals: Select Medical shareholders will sell their shares for $16.50 each in cash, while KORE shareholders will receive $9.25 per share, with Halper Sadeh LLC possibly seeking increased consideration and other remedies to protect shareholder interests.
  • Investor Rights Protection: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, highlighting its critical role in safeguarding investor rights.
PRnewswire
8.5
04-23PRnewswire
Investigation into Forian Inc. Merger Agreement
  • Board Investigation: Levi & Korsinsky, LLP has initiated an investigation into potential breaches of fiduciary duty by Forian Inc.'s Board of Directors regarding the merger agreement with a consortium of investors, which could impact shareholder rights.
  • Merger Agreement Details: Under the merger agreement, Forian shareholders, excluding those held by consortium members and affiliates, are expected to receive $2.17 per share in cash, a price that may be perceived as below market expectations.
  • Legal Consultation Services: Levi & Korsinsky offers no-cost legal consultations to assist Forian shareholders in understanding their rights and potentially providing legal support to affected investors, thereby enhancing their voice in the merger process.
  • Investor Protection: This investigation highlights concerns for Forian shareholders' interests, and if breaches are found, it could lead to a reassessment of the merger agreement, thereby affecting the company's future development and shareholder value.
PRnewswire
8.5
04-21PRnewswire
Investor Rights Law Firm Investigates Multiple Companies
  • Investigation Focus: Halper Sadeh LLC is investigating Forian Inc. (NASDAQ:FORA) for potential fiduciary duty breaches related to its sale to a consortium led by Max Wygod for $2.17 per share, which may adversely affect shareholder rights.
  • Merger Impact: The merger of Galera Therapeutics, Inc. (OTC:GRTX) with Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning only 1.8% of the combined entity, potentially diluting shareholder value and influence.
  • Acquisition Terms: Webster Financial Corporation (NYSE:WBS) is being sold to Banco Santander, S.A. for $48.75 in cash and 2.0548 Santander American Depository Shares per common share, which could significantly impact shareholder returns and future investment strategies.
  • Legal Rights Advocacy: Talkspace, Inc. (NASDAQ:TALK) is being sold to Universal Health Services, Inc. for $5.25 per share, and Halper Sadeh LLC is advocating for shareholders to seek increased consideration and additional disclosures to safeguard their legal rights.
Globenewswire
8.5
04-21Globenewswire
Monteverde Law Firm Investigates Multiple Mergers and Acquisitions
  • Globalstar Investigation: Monteverde & Associates is investigating the merger of Globalstar, Inc. with Amazon, where shareholders will receive $90 per share in cash or 0.3210 shares of Amazon stock, highlighting a commitment to shareholder value.
  • Galera Merger Details: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. will result in Galera shareholders owning approximately 1.8% of the combined entity, indicating strategic positioning in industry consolidation.
  • Webster Financial Transaction: Webster Financial Corporation shareholders are expected to receive $48.75 in cash and 2.0548 Santander American Depository Shares per common share, demonstrating the company's ability to create value through mergers.
  • Forian Share Sale: Forian Inc. shareholders are anticipated to receive $2.17 per share in cash, reflecting proactive measures in capital return strategies.
Globenewswire
8.5
04-15Globenewswire
Investor Rights Law Firm Investigates Multiple Companies
  • Investigation Focus: Halper Sadeh LLC is investigating Avanos Medical, Inc. (NYSE: AVNS) for potential violations of federal securities laws related to its sale to American Industrial Partners for $25.00 per share in cash, raising concerns about fiduciary duties to shareholders.
  • Shareholder Rights: Leggett & Platt, Incorporated (NYSE: LEG) is set to sell to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per Leggett share, resulting in Leggett shareholders owning approximately 9% of the combined entity, with Halper Sadeh LLC encouraging shareholders to explore their rights and options.
  • Cash Transaction: Soleno Therapeutics, Inc. (NASDAQ: SLNO) plans to sell to Neurocrine Biosciences for $53.00 per share in cash, prompting Halper Sadeh LLC to remind shareholders of their potential legal rights.
  • Management Involvement: Forian Inc. (NASDAQ: FORA) is being sold for $2.17 per share in cash to a consortium led by CEO Max Wygod, with Halper Sadeh LLC potentially seeking increased consideration and other remedies to protect shareholder interests.
Globenewswire
8.5
04-15Globenewswire
Investigations into Multiple Medical Company Mergers
  • Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
  • Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
  • Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
  • Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
Wall Street analysts forecast FORA stock price to rise
1 Analyst Rating
Wall Street analysts forecast FORA stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
2.10
Averages
2.10
High
2.10
Current: 0.000
sliders
Low
2.10
Averages
2.10
High
2.10
Roth Capital
Buy -> Neutral
downgrade
$5
AI Analysis
2025-11-17
Reason
Roth Capital
Price Target
$5
AI Analysis
2025-11-17
downgrade
Buy -> Neutral
Reason
Roth Capital downgraded Forian to Neutral from Buy with a price target of $2.10, down from $5.
Roth Capital
Richard Baldry
Buy -> Neutral
downgrade
$5
2025-11-17
Reason
Roth Capital
Richard Baldry
Price Target
$5
2025-11-17
downgrade
Buy -> Neutral
Reason
Roth Capital analyst Richard Baldry downgraded Forian to Neutral from Buy with a price target of $2.10, down from $5. The company reported good Q3 results but the shares offer little upside given the majority of shareholders have chosen to take Forian private at $2.10 per share, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FORA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Forian Inc. (FORA.O) is 23.87, compared to its 5-year average forward P/E of -10.70. For a more detailed relative valuation and DCF analysis to assess Forian Inc.'s fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.70
Current PE
23.87
Overvalued PE
13.68
Undervalued PE
-35.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
70.29
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
179.57
Undervalued EV/EBITDA
-39.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.36
Current PS
0.00
Overvalued PS
5.38
Undervalued PS
1.35

Financials

AI Analysis
Annual
Quarterly

Whales Holding FORA

S
Staley Capital Advisers, Inc.
Holding
FORA
+9.77%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Forian Inc. (FORA) stock price today?

The current price of FORA is 2.15 USD — it has increased 0

What is Forian Inc. (FORA)'s business?

Forian Inc. is a healthtech company. It is a provider of data science-driven information and analytics solutions to the life science, healthcare and financial services industries. It provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure the operational, clinical and financial performance of customers within the healthcare and life sciences and financial services industries. It has expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. Its solutions include CHRONOS, Chartis, real-world evidence (RWE) and Kyber Data Science. CHRONOS combines open and closed claims, electronic health records, and social determinants of health data into a single, integrated model. It also provides researchers access to healthcare payers, providers, and clinical data with non-traditional healthcare sources, such as social determinants of health (SDoH) data, to uncover novel insights.

What is the price predicton of FORA Stock?

Wall Street analysts forecast FORA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FORA is2.10 USD with a low forecast of 2.10 USD and a high forecast of 2.10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Forian Inc. (FORA)'s revenue for the last quarter?

Forian Inc. revenue for the last quarter amounts to 7.96M USD, increased 36.99

What is Forian Inc. (FORA)'s earnings per share (EPS) for the last quarter?

Forian Inc.. EPS for the last quarter amounts to -0.06 USD, decreased -700.00

How many employees does Forian Inc. (FORA). have?

Forian Inc. (FORA) has 50 emplpoyees as of May 11 2026.

What is Forian Inc. (FORA) market cap?

Today FORA has the market capitalization of 67.17M USD.